½ÃÀ庸°í¼­
»óǰÄÚµå
1819913

Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå º¸°í¼­ : ¿öÅ©Ç÷ο캰, ±â´Éº°, ¸ðµåº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)

Drug Discovery Informatics Market Report by Workflow, Function, Mode, End User (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organization, and Others), and Region 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 137 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå ±Ô¸ð´Â 2024³â 36¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â±îÁö ½ÃÀå ±Ô¸ð°¡ 84¾ï ´Þ·¯¿¡ ´ÞÇØ 2025³âºÎÅÍ 2033³â±îÁö 9.21%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

Drug Discovery ÀÎÆ÷¸Åƽ½º´Â ´ë·®ÀÇ »ýÈ­ÇÐ µ¥ÀÌÅ͸¦ ºÐ¼®Çϰí ÇØ¼®ÇÏ´Â µ¥ »ç¿ëµÇ´Â ±â¼ú ¼Ö·ç¼ÇÀÔ´Ï´Ù. µ¥ÀÌÅÍ´Â ¿¬±¸ ¸ñÀûÀ¸·Î ÀÓ»ó ½ÇÇè½Ç¿¡¼­ ¼öÇàµÈ ½ÇÇè¿¡¼­ »ý¼ºµÇ¸ç, ´Ù¾çÇÑ ¾à¹° °³¹ß¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ ¾ò±â À§ÇØ È°¿ëµË´Ï´Ù. ½ÃÄö½Ì, Ÿ°Ù µ¥ÀÌÅÍ ºÐ¼®, µ¥ÀÌÅÍ ½Ã°¢È­, µµÅ·, ºÐÀÚ ¸ðµ¨¸µ, ½Å¾à °³¹ßÀ» À§ÇÑ µ¥ÀÌÅͺ£À̽º º¸È£ µî ´Ù¾çÇÑ ¼ÒÇÁÆ®¿þ¾î ¹× Çϵå¿þ¾î ±â¹Ý µµ±¸°¡ Æ÷ÇԵ˴ϴÙ. ±× °á°ú, ÀÇ·á±â°ü, Á¦¾à-¹ÙÀÌ¿ÀÅØ ±â°ü, CRO(ÀǾàǰ °³¹ß ¾÷¹« À§Å¹±â°ü) µî¿¡¼­ ³Î¸® Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù.

Àü ¼¼°è ÇコÄÉ¾î ¹× Á¦¾à »ê¾÷ÀÇ °ý¸ñÇÒ¸¸ÇÑ ¼ºÀåÀº ½ÃÀå Àü¸ÁÀ» ¹à°Ô ¸¸µå´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡¿Í Èñ±Í Áúȯ Ä¡·á¿¡ ´ëÇÑ È¿°úÀûÀÎ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Drug Discovery ÀÎÆ÷¸Åƽ½º´Â Á¦¾àȸ»ç°¡ ½Å¾àÀÇ ½Çü¸¦ ºÐ¼®Çϰųª ¿©·¯ ÃâóÀÇ »ý¹°ÇÐÀû Á¤º¸¸¦ ´Ù·ê ¶§ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸ðµ¨¸µ°ú ½Ã¹Ä·¹À̼ÇÀ» ÅëÇØ ¾àµ¿ÇÐÀû °á°ú ¿¹ÃøÀ» Áö¿øÇÏ´Â Çõ½ÅÀûÀÎ »ý¸®Àû ¾àµ¿ÇÐ(PBPK) ½Ã¹Ä·¹ÀÌÅÍ Ç÷§Æû °³¹ß µî ´Ù¾çÇÑ ±â¼ú ¹ßÀüµµ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ¿ÀÆÝµå·° °³¹ßÀ» À§ÇÑ Á¤ºÎ ¹× ¹Î°£ ÀÇ·á±â°üÀÇ ÅõÀÚ Áõ°¡µµ ½ÃÀå °³Ã´¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ °í·É Àα¸ÀÇ Áõ°¡, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ºÐ¾ßÀÇ ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿ µîÀÌ ½ÃÀåÀ» ´õ¿í °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • ¼¼°è Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀåÀº Áö±Ý±îÁö ¾î¶»°Ô ¼ºÀåÇØ ¿ÔÀ»±î?
  • COVID-19°¡ ¼¼°è Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå¿¡ ¹ÌÄ£ ¿µÇâÀº?
  • ÁÖ¿ä Áö¿ª ½ÃÀåÀº?
  • ¿öÅ©Ç÷ο쿡 µû¸¥ ½ÃÀå ºÐ¼®Àº?
  • ±â´Éº° ½ÃÀå ºÐ¼®Àº?
  • ¸ðµåº° ½ÃÀå ºÐ¼®Àº?
  • ÃÖÁ¾»ç¿ëÀÚº° ½ÃÀå ºÐ¼®Àº ¾î¶»°Ô µÇ´Â°¡?
  • »ê¾÷ °¡Ä¡»ç½½ÀÇ ´Ù¾çÇÑ ´Ü°è´Â ¹«¾ùÀΰ¡?
  • ¾÷°èÀÇ ÁÖ¿ä ÃËÁø¿äÀΰú °úÁ¦´Â ¹«¾ùÀΰ¡?
  • ¼¼°è Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀåÀÇ ±¸Á¶¿Í ÁÖ¿ä Ç÷¹À̾î´Â?
  • ¾÷°è ³» °æÀïÀº ¾î´À Á¤µµÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

Á¦5Àå ¼¼°èÀÇ Drug Discovery ÀÎÆ÷¸Åƽ½º ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : ¿öÅ©Ç÷ο캰

  • Drug Discovery
  • Drug Development

Á¦7Àå ½ÃÀå ³»¿ª : ±â´Éº°

  • ¹è¿­ ÇØ¼® Ç÷§Æû
  • ºÐÀÚ ¸ðµ¨¸µ
  • ºÐÀÚ µµÅ·
  • ÀÓ»ó½ÃÇè µ¥ÀÌÅÍ °ü¸®
  • ±âŸ

Á¦8Àå ½ÃÀå ³»¿ª : ¸ðµåº°

  • ¾Æ¿ô¼Ò½Ì
  • ÀÎÇϿ콺

Á¦9Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

  • Á¦¾àȸ»ç
  • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • CRO
  • ±âŸ

Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå SWOT ºÐ¼®

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå Porter's Five Forces ºÐ¼®

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Accenture PLC
    • Certara
    • Charles River Laboratories Inc.
    • Collaborative Drug Discovery Inc.
    • Eurofins DiscoverX Products
    • Infosys Ltd.
    • International Business Machines Corporation
    • Jubilant Biosys Limited
    • Oracle Corporation
    • PerkinElmer Inc.
    • Selvita
    • Thermo Fisher Scientific Inc.
KSM 25.10.01

The global drug discovery informatics market size reached USD 3.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.4 Billion by 2033, exhibiting a growth rate (CAGR) of 9.21% during 2025-2033.

Drug discovery informatics is a technological solution used for analyzing and interpreting large volumes of biochemical data. The data is generated from the experiments conducted in clinical laboratories for research purposes and utilized for generating insights regarding the development of various drugs. It involves numerous software and hardware-based tools for sequencing, target data analysis, data visualization, docking, molecular modelling, database protection for drug discovery and development. As a result, it is widely used by healthcare institutions, pharmaceutical and biotechnology organizations and contract research organizations (CROs).

Significant growth in the healthcare and pharmaceutical industries across the globe represents one of key the factors creating a positive outlook for the market. Furthermore, the increasing prevalence of chronic medical disorders and the escalating requirement for effective solutions to treat rare diseases are also augmenting the market growth. Drug discovery informatics is widely used by pharmaceutical organizations for the analysis of new drug entities and handling of the biological information from multiple sources. Additionally, various technological advancements, such as the development of innovative Physiologically-based Pharmacokinetic (PBPK) Simulator platforms, which aid in predicting pharmacokinetic outcomes through modeling and simulation, are acting as other growth-inducing factors. In line with this, increasing investments by government and private healthcare institutions to develop orphan drugs is also contributing to the market growth. Other factors, including the rising geriatric population, along with extensive research and development (R&D) activities in the field of bioinformatics, are anticipated to drive the market further.

Key Market Segmentation:

Breakup by Workflow:

  • Drug Discovery
  • Drug Development

Breakup by Function:

  • Sequence Analysis Platforms
  • Molecular Modelling
  • Molecular Docking
  • Clinical Trial Data Management
  • Others

Breakup by Mode:

  • Outsourced
  • In-house

Breakup by End User:

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Contract Research Organization (CROs)
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Accenture Plc, Certara, Charles River Laboratories Inc., Collaborative Drug Discovery Inc., Eurofins DiscoverX Products, Infosys Ltd., International Business Machines Corporation, Jubilant Biosys Limited, Oracle Corporation, PerkinElmer Inc., Selvita and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

  • How has the global drug discovery informatics market performed so far and how will it perform in the coming years ?
  • What has been the impact of COVID-19 on the global drug discovery informatics market ?
  • What are the key regional markets ?
  • What is the breakup of the market based on the workflow ?
  • What is the breakup of the market based on the function ?
  • What is the breakup of the market based on the mode ?
  • What is the breakup of the market based on the end user ?
  • What are the various stages in the value chain of the industry ?
  • What are the key driving factors and challenges in the industry ?
  • What is the structure of the global drug discovery informatics market and who are the key players ?
  • What is the degree of competition in the industry ?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Drug Discovery Informatics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Workflow

  • 6.1 Drug Discovery
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Drug Development
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Function

  • 7.1 Sequence Analysis Platforms
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Molecular Modelling
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Molecular Docking
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Clinical Trial Data Management
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Mode

  • 8.1 Outsourced
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 In-house
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pharmaceutical Companies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Biotechnology Companies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Contract Research Organization (CROs)
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Accenture PLC
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Certara
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Charles River Laboratories Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Collaborative Drug Discovery Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 Eurofins DiscoverX Products
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Infosys Ltd.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 International Business Machines Corporation
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Jubilant Biosys Limited
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Oracle Corporation
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 PerkinElmer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Selvita
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
    • 15.3.12 Thermo Fisher Scientific Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦